Vyvanse Compounding Legal Status: FDA Rules, DEA Restrictions, and What Patients Need to Know
Yes, lisdexamfetamine (Vyvanse) is a Schedule II controlled substance because it can be abused or lead to dependence. The FDA label has a boxed warning.
Vyvanse: Regulatory History
4 source-based articles maintained by the HealthRX.com Editorial Team.
4articles
2topic areas covered
May 25, 2026latest review
Vyvanse: Regulatory History library
Showing 4 of 4 clinical reviews.
Vyvanse FDA Approval History: Every Regulatory Milestone from 2007 to Generic Entry
A timeline of Vyvanse (lisdexamfetamine) FDA approvals, label expansions, safety updates, and generic entry, with sourcing notes on which claims are FDA-confirmed and which require primary-literature verification.
Vyvanse Global Regulatory Status: FDA Approval, International Scheduling, and Post-Market Surveillance
A comprehensive review of lisdexamfetamine (Vyvanse) regulatory status worldwide, including FDA approval history, EMA authorization, scheduling classifications, label updates, and ongoing safety monitoring.
Vyvanse Legal and Patent Challenges: FDA History, Litigation, and Generic Entry
A detailed review of Vyvanse (lisdexamfetamine) patent litigation, Hatch-Waxman challenges, FDA approval timeline, and the path to generic availability.